The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Gastric Carcinomas Drugs Market Research Report 2025

Global Gastric Carcinomas Drugs Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1797031

No of Pages : 80

Synopsis
Gastric Carcinomas is a cancer of the gastric mucosa. Early symptoms include heartburn, upper abdominal pain, nausea, and loss of appetite. Symptoms are similar to those of peptic ulcers, leading to delayed treatment and a high mortality rate.
The global Gastric Carcinomas Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Gastric Carcinomas Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gastric Carcinomas Drugs.
Report Scope
The Gastric Carcinomas Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Gastric Carcinomas Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Gastric Carcinomas Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Novo Nordisk
Bayer
Merck & Co
Roche
Eli Lilly and Company
Taiho Pharmaceutical
Jiangsu Hengrui Medicine Company Limited
Fujian Haiwang Fuyao Pharmacy Limited Company
Qilu Pharma
Shandong New Era Hotel Pharmaceutical Industry Limited Company
Chiatai Tianqing
Segment by Type
First Line Treatment
Second Line Treatment
Three Line Treatment
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Gastric Carcinomas Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Gastric Carcinomas Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 First Line Treatment
1.2.3 Second Line Treatment
1.2.4 Three Line Treatment
1.3 Market by Application
1.3.1 Global Gastric Carcinomas Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Gastric Carcinomas Drugs Market Perspective (2019-2030)
2.2 Gastric Carcinomas Drugs Growth Trends by Region
2.2.1 Global Gastric Carcinomas Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Gastric Carcinomas Drugs Historic Market Size by Region (2019-2024)
2.2.3 Gastric Carcinomas Drugs Forecasted Market Size by Region (2025-2030)
2.3 Gastric Carcinomas Drugs Market Dynamics
2.3.1 Gastric Carcinomas Drugs Industry Trends
2.3.2 Gastric Carcinomas Drugs Market Drivers
2.3.3 Gastric Carcinomas Drugs Market Challenges
2.3.4 Gastric Carcinomas Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Gastric Carcinomas Drugs Players by Revenue
3.1.1 Global Top Gastric Carcinomas Drugs Players by Revenue (2019-2024)
3.1.2 Global Gastric Carcinomas Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Gastric Carcinomas Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Gastric Carcinomas Drugs Revenue
3.4 Global Gastric Carcinomas Drugs Market Concentration Ratio
3.4.1 Global Gastric Carcinomas Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Gastric Carcinomas Drugs Revenue in 2023
3.5 Gastric Carcinomas Drugs Key Players Head office and Area Served
3.6 Key Players Gastric Carcinomas Drugs Product Solution and Service
3.7 Date of Enter into Gastric Carcinomas Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Gastric Carcinomas Drugs Breakdown Data by Type
4.1 Global Gastric Carcinomas Drugs Historic Market Size by Type (2019-2024)
4.2 Global Gastric Carcinomas Drugs Forecasted Market Size by Type (2025-2030)
5 Gastric Carcinomas Drugs Breakdown Data by Application
5.1 Global Gastric Carcinomas Drugs Historic Market Size by Application (2019-2024)
5.2 Global Gastric Carcinomas Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Gastric Carcinomas Drugs Market Size (2019-2030)
6.2 North America Gastric Carcinomas Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Gastric Carcinomas Drugs Market Size by Country (2019-2024)
6.4 North America Gastric Carcinomas Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Gastric Carcinomas Drugs Market Size (2019-2030)
7.2 Europe Gastric Carcinomas Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Gastric Carcinomas Drugs Market Size by Country (2019-2024)
7.4 Europe Gastric Carcinomas Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Gastric Carcinomas Drugs Market Size (2019-2030)
8.2 Asia-Pacific Gastric Carcinomas Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Gastric Carcinomas Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Gastric Carcinomas Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Gastric Carcinomas Drugs Market Size (2019-2030)
9.2 Latin America Gastric Carcinomas Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Gastric Carcinomas Drugs Market Size by Country (2019-2024)
9.4 Latin America Gastric Carcinomas Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Gastric Carcinomas Drugs Market Size (2019-2030)
10.2 Middle East & Africa Gastric Carcinomas Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Gastric Carcinomas Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Gastric Carcinomas Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Gastric Carcinomas Drugs Introduction
11.1.4 Pfizer Revenue in Gastric Carcinomas Drugs Business (2019-2024)
11.1.5 Pfizer Recent Development
11.2 Novo Nordisk
11.2.1 Novo Nordisk Company Detail
11.2.2 Novo Nordisk Business Overview
11.2.3 Novo Nordisk Gastric Carcinomas Drugs Introduction
11.2.4 Novo Nordisk Revenue in Gastric Carcinomas Drugs Business (2019-2024)
11.2.5 Novo Nordisk Recent Development
11.3 Bayer
11.3.1 Bayer Company Detail
11.3.2 Bayer Business Overview
11.3.3 Bayer Gastric Carcinomas Drugs Introduction
11.3.4 Bayer Revenue in Gastric Carcinomas Drugs Business (2019-2024)
11.3.5 Bayer Recent Development
11.4 Merck & Co
11.4.1 Merck & Co Company Detail
11.4.2 Merck & Co Business Overview
11.4.3 Merck & Co Gastric Carcinomas Drugs Introduction
11.4.4 Merck & Co Revenue in Gastric Carcinomas Drugs Business (2019-2024)
11.4.5 Merck & Co Recent Development
11.5 Roche
11.5.1 Roche Company Detail
11.5.2 Roche Business Overview
11.5.3 Roche Gastric Carcinomas Drugs Introduction
11.5.4 Roche Revenue in Gastric Carcinomas Drugs Business (2019-2024)
11.5.5 Roche Recent Development
11.6 Eli Lilly and Company
11.6.1 Eli Lilly and Company Company Detail
11.6.2 Eli Lilly and Company Business Overview
11.6.3 Eli Lilly and Company Gastric Carcinomas Drugs Introduction
11.6.4 Eli Lilly and Company Revenue in Gastric Carcinomas Drugs Business (2019-2024)
11.6.5 Eli Lilly and Company Recent Development
11.7 Taiho Pharmaceutical
11.7.1 Taiho Pharmaceutical Company Detail
11.7.2 Taiho Pharmaceutical Business Overview
11.7.3 Taiho Pharmaceutical Gastric Carcinomas Drugs Introduction
11.7.4 Taiho Pharmaceutical Revenue in Gastric Carcinomas Drugs Business (2019-2024)
11.7.5 Taiho Pharmaceutical Recent Development
11.8 Jiangsu Hengrui Medicine Company Limited
11.8.1 Jiangsu Hengrui Medicine Company Limited Company Detail
11.8.2 Jiangsu Hengrui Medicine Company Limited Business Overview
11.8.3 Jiangsu Hengrui Medicine Company Limited Gastric Carcinomas Drugs Introduction
11.8.4 Jiangsu Hengrui Medicine Company Limited Revenue in Gastric Carcinomas Drugs Business (2019-2024)
11.8.5 Jiangsu Hengrui Medicine Company Limited Recent Development
11.9 Fujian Haiwang Fuyao Pharmacy Limited Company
11.9.1 Fujian Haiwang Fuyao Pharmacy Limited Company Company Detail
11.9.2 Fujian Haiwang Fuyao Pharmacy Limited Company Business Overview
11.9.3 Fujian Haiwang Fuyao Pharmacy Limited Company Gastric Carcinomas Drugs Introduction
11.9.4 Fujian Haiwang Fuyao Pharmacy Limited Company Revenue in Gastric Carcinomas Drugs Business (2019-2024)
11.9.5 Fujian Haiwang Fuyao Pharmacy Limited Company Recent Development
11.10 Qilu Pharma
11.10.1 Qilu Pharma Company Detail
11.10.2 Qilu Pharma Business Overview
11.10.3 Qilu Pharma Gastric Carcinomas Drugs Introduction
11.10.4 Qilu Pharma Revenue in Gastric Carcinomas Drugs Business (2019-2024)
11.10.5 Qilu Pharma Recent Development
11.11 Shandong New Era Hotel Pharmaceutical Industry Limited Company
11.11.1 Shandong New Era Hotel Pharmaceutical Industry Limited Company Company Detail
11.11.2 Shandong New Era Hotel Pharmaceutical Industry Limited Company Business Overview
11.11.3 Shandong New Era Hotel Pharmaceutical Industry Limited Company Gastric Carcinomas Drugs Introduction
11.11.4 Shandong New Era Hotel Pharmaceutical Industry Limited Company Revenue in Gastric Carcinomas Drugs Business (2019-2024)
11.11.5 Shandong New Era Hotel Pharmaceutical Industry Limited Company Recent Development
11.12 Chiatai Tianqing
11.12.1 Chiatai Tianqing Company Detail
11.12.2 Chiatai Tianqing Business Overview
11.12.3 Chiatai Tianqing Gastric Carcinomas Drugs Introduction
11.12.4 Chiatai Tianqing Revenue in Gastric Carcinomas Drugs Business (2019-2024)
11.12.5 Chiatai Tianqing Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
List of Tables
Table 1. Global Gastric Carcinomas Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of First Line Treatment
Table 3. Key Players of Second Line Treatment
Table 4. Key Players of Three Line Treatment
Table 5. Global Gastric Carcinomas Drugs Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Gastric Carcinomas Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Gastric Carcinomas Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Gastric Carcinomas Drugs Market Share by Region (2019-2024)
Table 9. Global Gastric Carcinomas Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Gastric Carcinomas Drugs Market Share by Region (2025-2030)
Table 11. Gastric Carcinomas Drugs Market Trends
Table 12. Gastric Carcinomas Drugs Market Drivers
Table 13. Gastric Carcinomas Drugs Market Challenges
Table 14. Gastric Carcinomas Drugs Market Restraints
Table 15. Global Gastric Carcinomas Drugs Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Gastric Carcinomas Drugs Market Share by Players (2019-2024)
Table 17. Global Top Gastric Carcinomas Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gastric Carcinomas Drugs as of 2023)
Table 18. Ranking of Global Top Gastric Carcinomas Drugs Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Gastric Carcinomas Drugs Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Gastric Carcinomas Drugs Product Solution and Service
Table 22. Date of Enter into Gastric Carcinomas Drugs Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Gastric Carcinomas Drugs Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Gastric Carcinomas Drugs Revenue Market Share by Type (2019-2024)
Table 26. Global Gastric Carcinomas Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Gastric Carcinomas Drugs Revenue Market Share by Type (2025-2030)
Table 28. Global Gastric Carcinomas Drugs Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Gastric Carcinomas Drugs Revenue Market Share by Application (2019-2024)
Table 30. Global Gastric Carcinomas Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Gastric Carcinomas Drugs Revenue Market Share by Application (2025-2030)
Table 32. North America Gastric Carcinomas Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Gastric Carcinomas Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Gastric Carcinomas Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Gastric Carcinomas Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Gastric Carcinomas Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Gastric Carcinomas Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Gastric Carcinomas Drugs Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Gastric Carcinomas Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Gastric Carcinomas Drugs Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Gastric Carcinomas Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Gastric Carcinomas Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Gastric Carcinomas Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Gastric Carcinomas Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Gastric Carcinomas Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Gastric Carcinomas Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 47. Pfizer Company Detail
Table 48. Pfizer Business Overview
Table 49. Pfizer Gastric Carcinomas Drugs Product
Table 50. Pfizer Revenue in Gastric Carcinomas Drugs Business (2019-2024) & (US$ Million)
Table 51. Pfizer Recent Development
Table 52. Novo Nordisk Company Detail
Table 53. Novo Nordisk Business Overview
Table 54. Novo Nordisk Gastric Carcinomas Drugs Product
Table 55. Novo Nordisk Revenue in Gastric Carcinomas Drugs Business (2019-2024) & (US$ Million)
Table 56. Novo Nordisk Recent Development
Table 57. Bayer Company Detail
Table 58. Bayer Business Overview
Table 59. Bayer Gastric Carcinomas Drugs Product
Table 60. Bayer Revenue in Gastric Carcinomas Drugs Business (2019-2024) & (US$ Million)
Table 61. Bayer Recent Development
Table 62. Merck & Co Company Detail
Table 63. Merck & Co Business Overview
Table 64. Merck & Co Gastric Carcinomas Drugs Product
Table 65. Merck & Co Revenue in Gastric Carcinomas Drugs Business (2019-2024) & (US$ Million)
Table 66. Merck & Co Recent Development
Table 67. Roche Company Detail
Table 68. Roche Business Overview
Table 69. Roche Gastric Carcinomas Drugs Product
Table 70. Roche Revenue in Gastric Carcinomas Drugs Business (2019-2024) & (US$ Million)
Table 71. Roche Recent Development
Table 72. Eli Lilly and Company Company Detail
Table 73. Eli Lilly and Company Business Overview
Table 74. Eli Lilly and Company Gastric Carcinomas Drugs Product
Table 75. Eli Lilly and Company Revenue in Gastric Carcinomas Drugs Business (2019-2024) & (US$ Million)
Table 76. Eli Lilly and Company Recent Development
Table 77. Taiho Pharmaceutical Company Detail
Table 78. Taiho Pharmaceutical Business Overview
Table 79. Taiho Pharmaceutical Gastric Carcinomas Drugs Product
Table 80. Taiho Pharmaceutical Revenue in Gastric Carcinomas Drugs Business (2019-2024) & (US$ Million)
Table 81. Taiho Pharmaceutical Recent Development
Table 82. Jiangsu Hengrui Medicine Company Limited Company Detail
Table 83. Jiangsu Hengrui Medicine Company Limited Business Overview
Table 84. Jiangsu Hengrui Medicine Company Limited Gastric Carcinomas Drugs Product
Table 85. Jiangsu Hengrui Medicine Company Limited Revenue in Gastric Carcinomas Drugs Business (2019-2024) & (US$ Million)
Table 86. Jiangsu Hengrui Medicine Company Limited Recent Development
Table 87. Fujian Haiwang Fuyao Pharmacy Limited Company Company Detail
Table 88. Fujian Haiwang Fuyao Pharmacy Limited Company Business Overview
Table 89. Fujian Haiwang Fuyao Pharmacy Limited Company Gastric Carcinomas Drugs Product
Table 90. Fujian Haiwang Fuyao Pharmacy Limited Company Revenue in Gastric Carcinomas Drugs Business (2019-2024) & (US$ Million)
Table 91. Fujian Haiwang Fuyao Pharmacy Limited Company Recent Development
Table 92. Qilu Pharma Company Detail
Table 93. Qilu Pharma Business Overview
Table 94. Qilu Pharma Gastric Carcinomas Drugs Product
Table 95. Qilu Pharma Revenue in Gastric Carcinomas Drugs Business (2019-2024) & (US$ Million)
Table 96. Qilu Pharma Recent Development
Table 97. Shandong New Era Hotel Pharmaceutical Industry Limited Company Company Detail
Table 98. Shandong New Era Hotel Pharmaceutical Industry Limited Company Business Overview
Table 99. Shandong New Era Hotel Pharmaceutical Industry Limited Company Gastric Carcinomas Drugs Product
Table 100. Shandong New Era Hotel Pharmaceutical Industry Limited Company Revenue in Gastric Carcinomas Drugs Business (2019-2024) & (US$ Million)
Table 101. Shandong New Era Hotel Pharmaceutical Industry Limited Company Recent Development
Table 102. Chiatai Tianqing Company Detail
Table 103. Chiatai Tianqing Business Overview
Table 104. Chiatai Tianqing Gastric Carcinomas Drugs Product
Table 105. Chiatai Tianqing Revenue in Gastric Carcinomas Drugs Business (2019-2024) & (US$ Million)
Table 106. Chiatai Tianqing Recent Development
Table 107. Research Programs/Design for This Report
Table 108. Key Data Information from Secondary Sources
Table 109. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Gastric Carcinomas Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Gastric Carcinomas Drugs Market Share by Type: 2023 VS 2030
Figure 3. First Line Treatment Features
Figure 4. Second Line Treatment Features
Figure 5. Three Line Treatment Features
Figure 6. Global Gastric Carcinomas Drugs Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Gastric Carcinomas Drugs Market Share by Application: 2023 VS 2030
Figure 8. Hospital Case Studies
Figure 9. Clinic Case Studies
Figure 10. Others Case Studies
Figure 11. Gastric Carcinomas Drugs Report Years Considered
Figure 12. Global Gastric Carcinomas Drugs Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 13. Global Gastric Carcinomas Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Gastric Carcinomas Drugs Market Share by Region: 2023 VS 2030
Figure 15. Global Gastric Carcinomas Drugs Market Share by Players in 2023
Figure 16. Global Top Gastric Carcinomas Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gastric Carcinomas Drugs as of 2023)
Figure 17. The Top 10 and 5 Players Market Share by Gastric Carcinomas Drugs Revenue in 2023
Figure 18. North America Gastric Carcinomas Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. North America Gastric Carcinomas Drugs Market Share by Country (2019-2030)
Figure 20. United States Gastric Carcinomas Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Canada Gastric Carcinomas Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Gastric Carcinomas Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Gastric Carcinomas Drugs Market Share by Country (2019-2030)
Figure 24. Germany Gastric Carcinomas Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. France Gastric Carcinomas Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. U.K. Gastric Carcinomas Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Italy Gastric Carcinomas Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Russia Gastric Carcinomas Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Nordic Countries Gastric Carcinomas Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Gastric Carcinomas Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Gastric Carcinomas Drugs Market Share by Region (2019-2030)
Figure 32. China Gastric Carcinomas Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Japan Gastric Carcinomas Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. South Korea Gastric Carcinomas Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Southeast Asia Gastric Carcinomas Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. India Gastric Carcinomas Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Australia Gastric Carcinomas Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Gastric Carcinomas Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Gastric Carcinomas Drugs Market Share by Country (2019-2030)
Figure 40. Mexico Gastric Carcinomas Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Brazil Gastric Carcinomas Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Gastric Carcinomas Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Gastric Carcinomas Drugs Market Share by Country (2019-2030)
Figure 44. Turkey Gastric Carcinomas Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Saudi Arabia Gastric Carcinomas Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Pfizer Revenue Growth Rate in Gastric Carcinomas Drugs Business (2019-2024)
Figure 47. Novo Nordisk Revenue Growth Rate in Gastric Carcinomas Drugs Business (2019-2024)
Figure 48. Bayer Revenue Growth Rate in Gastric Carcinomas Drugs Business (2019-2024)
Figure 49. Merck & Co Revenue Growth Rate in Gastric Carcinomas Drugs Business (2019-2024)
Figure 50. Roche Revenue Growth Rate in Gastric Carcinomas Drugs Business (2019-2024)
Figure 51. Eli Lilly and Company Revenue Growth Rate in Gastric Carcinomas Drugs Business (2019-2024)
Figure 52. Taiho Pharmaceutical Revenue Growth Rate in Gastric Carcinomas Drugs Business (2019-2024)
Figure 53. Jiangsu Hengrui Medicine Company Limited Revenue Growth Rate in Gastric Carcinomas Drugs Business (2019-2024)
Figure 54. Fujian Haiwang Fuyao Pharmacy Limited Company Revenue Growth Rate in Gastric Carcinomas Drugs Business (2019-2024)
Figure 55. Qilu Pharma Revenue Growth Rate in Gastric Carcinomas Drugs Business (2019-2024)
Figure 56. Shandong New Era Hotel Pharmaceutical Industry Limited Company Revenue Growth Rate in Gastric Carcinomas Drugs Business (2019-2024)
Figure 57. Chiatai Tianqing Revenue Growth Rate in Gastric Carcinomas Drugs Business (2019-2024)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed

Published By : QY Research

Why ‘The Market Reports’